London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
But good or bad Nolo? I had hoped for an RNS re the FDA and Phase 3 trial protocols etc.
Well I was right about the rns, but not one I had thought of. This is actually a positive in my view as there will be less dilution of the shares and the board can pay from funds held.I think we will see this bump upwards at open - not much, but 12p easily possible. The real meat on the bone here is FDA related or an update on Ureka.
Easyp ,
This is very unusual and therefore it's a warning flag but without knowing more can we really say that this is good or bad for us ?
Only time will tell
Avion submitted a special protocol assessment (SPA) request to the US regulators with the aim of streamlining the approval process for the clinical trial.
Discussions with a number of potential commercial partners outside the US – so further commercial upside for the drug.
The Avion deal will see ImmuPharma receive up to US$70mln of milestone payments, with US$5mln due on regulatory approval of the product and a further US$65mln dependent on sales targets.
The UK group will also get royalties of up to 17% on sales, while there are financial incentives to expand Lupuzor’s use into other autoimmune diseases.
The future is bright and the potential is massive.
In the highlights section of the RNS dated 11 June I think they should have mentioned that they have to right to basically a refund
Less dilution is great
Not sure if it is a good thing but the company is still the one we have grown to love.
Lind still hold a substantial amount of shares sold are still invested here.
Lind will now be looking to buy at the market price as opposed to converting at 17p.
Look at the terms of the investment announced in June 2020:
At any time, during the maturity period, the Investors may convert their Securities (in whole or in part) to 13,086,619 ordinary shares in the Company, in aggregate, at a price of 17.96p ("Conversion Price") which is equivalent to 120% of the Volume Weighted Average Price ("VWAP") of the ordinary shares for 09 June 2020.
During the maturity period, the Company may require the investors to convert their securities to ordinary shares, if the VWAP on each of at least 20 consecutive trading days shall be equal to or have exceeded 35.92p (200% of the Conversion Price).
I’m hoping to see the latter and volume weighted average price above 35.92.
Let’s see who can read between the lines on this one.
Eva
Where is your 100k going?
EVA i cant tell you what to do if u sell now u lose more than 20 percent .Due to size of your trade unless you sell in 50k lots . Any way been there before with imm in the early days sold at a loss .UNTIL i worked out how imm works .If IT WAS ME I WOULD WAIT .But thats me please dont los money it is hard to get back . Patience always wins .I WISH you well
EVA IF U SELL have a break and chill -Sometimes better not to overtrade atb
Great to see one of the money lenders gone.
How for FDA decision and other news.
Lind will be able to buy in at lower than what they had to convert for........should see this as a postive. Also they may be aware that news is imminent, as I can see this as a start of positive newsflow!
]
Incanthera news a big beat on skin cancer treatment and we own 17% over there
Maverickd,
LInd and L1 have a conversion price of 11p .....
Investors will be buying here
FDA/SPA news imminent
Ureka update due
Peptide research ongoing
Exposure to Incanthera
Avion to pay $70m in milestone payments and 17% royalty going forward
Analysts have stated that the potential sales for Lupazor would top $1bil so royalty payments would be in the region of $170m per annum
Major shareholders still on board
I get the feeling that Lind could well be relatively transient with not a great amount of funds to play wit hand like us were waiting for news.
So like Eva they are getting back some working capital and putting it elsewhere.
Well we are in the blue surprised more aren't buying, but it's early I guess